Department of Interventional Cardiology, Medical University of Lodz, Central Clinical Hospital, ul. Pomorska 251, Lodz 92-213, Poland.
Department of Rheumatology, Medical University of Lodz, Pieniny 30, Lodz 92-113, Poland.
Cardiol Clin. 2020 Nov;38(4):629-637. doi: 10.1016/j.ccl.2020.07.009. Epub 2020 Sep 17.
The article discusses pharmacologic and interventional therapeutic options for patients with refractory angina. Refractory angina refers to long-lasting symptoms (≥3 months) due to established reversible ischemia in the presence of obstructive coronary artery disease, which cannot be controlled by escalating medical therapy with second-line and third-line pharmacologic agents, bypass grafting, or stenting. Due to an aging population, increased number of comorbidities, and advances in coronary artery disease treatment, incidence of refractory angina is growing. Although the number of therapeutic options is increasing, there is a lack of randomized clinical trials that could help create recommendations for this group of patients.
本文讨论了耐治疗性心绞痛患者的药物和介入治疗选择。耐治疗性心绞痛是指在存在阻塞性冠状动脉疾病的情况下,由于已经确立的可逆性缺血引起的持续时间长的症状(≥3 个月),二线和三线药物治疗、旁路移植或支架置入等不能控制这些症状。由于人口老龄化、合并症增多以及冠状动脉疾病治疗的进步,耐治疗性心绞痛的发病率正在增加。尽管治疗选择的数量在增加,但缺乏随机临床试验来帮助为这组患者制定建议。